Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2007-04-03
2007-04-03
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S004000, C435S007100, C514S002600, C530S300000, C530S326000, C424S184100, C424S189100, C424S228100
Reexamination Certificate
active
11090952
ABSTRACT:
The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4astarting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.
REFERENCES:
patent: 5302507 (1994-04-01), Chiba et al.
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6881821 (2005-04-01), Simmonds et al.
patent: 42 09 215 (1992-03-01), None
patent: 0 318-216 (1989-05-01), None
patent: 0 518 313 (1992-12-01), None
patent: WO 93/10239 (1993-05-01), None
patent: WO 94/25601 (1994-11-01), None
patent: WO 95/11918 (1995-05-01), None
Berzofsky et al., “Process on new vaccine strategies against chronic viral infections,” The Journal of Clinical Investigation, vol. 114 No. 4, pp. 450-462 (Aug. 2004).
Definition “vaccine”, The On-line Medical Dictionary, cancerweb.ncl.ac.uk/omd, 2006.
LeRoux-Roels, Development of prophylactic and therapeutic vaccines against hepatitis C virus, Expert Review of Vaccines, vol. 4 No. 3, pp. 351-371 (Jun. 2005).
Liang et al., “Pathogenesis, natural history, treatment, and prevention of hepatitis C,” Annals of Internal Medicine, vol. 132 No. 4, pp. 296-305 (Feb. 2000).
Rollier et al., “Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response,” Journal of Virology, vol. 78 No. 1, pp. 187-196 (Jan. 2004).
Tan et al., “Strategies for hepatitis C therapeutic intervention: now and next ,”Current Opinion in Pharmacology, vol. 4 No. 5, pp. 465-470 (Oct. 2004).
Tam et al., “Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-Density Multiple Antigenic Peptide System,” Proceedings of the National Academy of Sciences, USA, vol. 85 No. 15, pp. 5409/5413 (Aug. 1988).
Cha, T.A., et al., “At Lease Five Related, But Distinct, Hepatitis C Viral Genotypes Exist,”Proc. Natl. Acad. Sci. USA, Aug. 1, 1992, pp. 7144-7148, vol. 89, No. 15.
Chan, S. W., et al., “Analysis of a New Hepatitis C Virus Type and Its Phylogenetic Relationship to Existing Variants,”Journal of General Virology, 1992, pp. 1131-1141, vol. 73.
Farci, P., et al., “Immunity Elicited by Hepatitis C. Virus,”Gastroenterology, Apr. 1993, pp. 1228-1229, vol. 104, No. 4.
Marguerite, M., et al., “Analysis of Antigenicity and Immunogenicity of Five Different Chemically Defined Constructs of a Peptide,”Mol. Immunol., Jun. 1992, pp. 793-800, vol. 29, No. 6.
Prince, A.M., “Challenges for Development of Hepatitis C Virus Vaccines,”FEMS Microbiol. Rev., Jul. 1994, pp. 273-277, vol. 14, No. 3.
Simmonds, P., et al., “Sequence Variability in the 5′ Non-coding Region of Hepatitis C Virus: Identification of a new Virus Type and Restrictions on Sequence Diversity,”Journal of General Virology, 1993, pp. 661-668, vol. 74.
Simmonds, P., et al., “Classification of Hepatitis C Virus Into Six Major Genotypes and a Series of Subtypes by Phylogenetic Analysis of the NS-5 Region,”Journal of General Virology, 1993, pp. 2391-2399, vol. 74.
Pike Ian Hugo
Simmonds Peter
Yap Peng Lee
Alston & Bird LLP
Campell Bruce R.
Common Services Agency
Lucas Zachariah
LandOfFree
Hepatitis-C virus type 4, 5 and 6 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis-C virus type 4, 5 and 6, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis-C virus type 4, 5 and 6 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724009